Correction to “Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1)”
{"title":"Correction to “Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1)”","authors":"","doi":"10.1002/jhbp.12096","DOIUrl":null,"url":null,"abstract":"<p>Naohiro O, Manabu K, Makoto U, Xianjun Y, Yosuke I, Shinichiro T, et al. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1). <i>J Hepatobiliary Pancreat Sci</i>. 2024;31:816-829. https://doi.org/10.1002/jhbp.12066</p><p>In section 3.3 Adjuvant therapy and mode of relapse, the sentence “Among these patients, 51 (26.3%) experienced relapse. The most common sites were the liver (18.0%), local (17.5%), lungs (17.0%), and peritoneum (11.3%).” should read as below,</p><p>“Among these patients, 143 (73.7%) experienced relapse. The most common sites were the liver (19.1%), local (18.0%), lungs (18.0%), and peritoneum (12.9%).”</p><p>We apologize for this error.</p>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":"32 2","pages":"177"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jhbp.12096","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepato‐Biliary‐Pancreatic Sciences","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jhbp.12096","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Naohiro O, Manabu K, Makoto U, Xianjun Y, Yosuke I, Shinichiro T, et al. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1). J Hepatobiliary Pancreat Sci. 2024;31:816-829. https://doi.org/10.1002/jhbp.12066
In section 3.3 Adjuvant therapy and mode of relapse, the sentence “Among these patients, 51 (26.3%) experienced relapse. The most common sites were the liver (18.0%), local (17.5%), lungs (17.0%), and peritoneum (11.3%).” should read as below,
“Among these patients, 143 (73.7%) experienced relapse. The most common sites were the liver (19.1%), local (18.0%), lungs (18.0%), and peritoneum (12.9%).”
O直宏，K Manabu, U Makoto, Y Xianjun, I Yosuke, T Shinichiro，等。一项多中心回顾性队列研究（PC-CURE-1）：最初不可切除的胰腺癌患者在FOLFIRINOX或吉西他滨加nab-紫杉醇化疗后接受转换手术的结果。[J]中华肝胆胰脏杂志，2014;31(1):816-829。https://doi.org/10.1002/jhbp.12066In第3.3节辅助治疗和复发方式，句子“在这些患者中，51例（26.3%）复发。最常见的部位是肝脏（18.0%）、局部（17.5%）、肺部（17.0%）和腹膜（11.3%）。应如下所述：“在这些患者中，143例（73.7%）复发。最常见的部位是肝脏（19.1%）、局部（18.0%）、肺部（18.0%）和腹膜（12.9%）。我们为这个错误道歉。
期刊介绍：
The Journal of Hepato-Biliary-Pancreatic Sciences (JHBPS) is the leading peer-reviewed journal in the field of hepato-biliary-pancreatic sciences. JHBPS publishes articles dealing with clinical research as well as translational research on all aspects of this field. Coverage includes Original Article, Review Article, Images of Interest, Rapid Communication and an announcement section. Letters to the Editor and comments on the journal’s policies or content are also included. JHBPS welcomes submissions from surgeons, physicians, endoscopists, radiologists, oncologists, and pathologists.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
